• COVID-19: Endemic Disease
  • Products
    • ASSURE-100 Home Tests
    • ASSURE-100 POC Tests
    • Buy ASSURE-100 Tests
  • News & Updates
  • Contact Us
Buy Tests
  • COVID-19: Endemic Disease
  • Products
    • ASSURE-100 Home Tests
    • ASSURE-100 POC Tests
    • Buy ASSURE-100 Tests
  • News & Updates
  • Contact Us
  • BUY TESTS
PRESS RELEASE | Free ASSURE-100 Rapid Tests for Kūpuna and At-Risk Hawai’i Residents as Federal Support Ends

PRESS RELEASE | Free ASSURE-100 Rapid Tests for Kūpuna and At-Risk Hawai’i Residents as Federal Support Ends

by Oceanit | Apr 26, 2023 | Government, National News

PRESS RELEASE | Free ASSURE-100 Rapid Tests for Kūpuna and At-Risk Hawai’i Residents as Federal Support Ends Honolulu, HI April 26, 2023 | On May 11th, 2023 the U.S. federal government will officially end the COVID-19 Public Health Emergency (“PHE”) that began three...
PRESS RELEASE | Oceanit Receives FDA Emergency Use Authorization for ASSURE-100 Rapid COVID-19 Tests

PRESS RELEASE | Oceanit Receives FDA Emergency Use Authorization for ASSURE-100 Rapid COVID-19 Tests

by Oceanit | Feb 28, 2022 | Government, International News, National News

PRESS RELEASE | Oceanit Receives FDA Emergency Use Authorization for ASSURE-100 Rapid COVID-19 Tests FOR IMMEDIATE RELEASE ASSURE-100 Rapid COVID-19 Tests quickly and reliably detect all variants of SARS-CoV-2, including the delta and omicron. Simple, easy to use and...
PRESS RELEASE | National Institutes of Health Approves Next Round of ASSURE-19 Funding Under the RADx ‘Next’ Program

PRESS RELEASE | National Institutes of Health Approves Next Round of ASSURE-19 Funding Under the RADx ‘Next’ Program

by Oceanit | Oct 8, 2020 | Government, National News

PRESS RELEASE | National Institutes of Health Approves Next Round of ASSURE-19 Funding Under the RADx ‘Next’ Program Honolulu, HI | Oceanit Laboratories received approval from NIH for next round funding under the RADx initiative, receiving an additional $250,000 for...
PRESS RELEASE | Oceanit Selected As a Semi-Finalist For the XPRIZE Rapid Covid Testing Competition

PRESS RELEASE | Oceanit Selected As a Semi-Finalist For the XPRIZE Rapid Covid Testing Competition

by Oceanit | Sep 16, 2020 | Future, International News

PRESS RELEASE | Oceanit Selected As a Semi-Finalist For the XPRIZE Rapid Covid Testing Competition Oceanit’s ASSURE-19 Covid-19 test was selected as a semi-finalist from a pool of nearly 700 teams from around the world competing in the XPRIZE Rapid Covid Testing...
PRESS RELEASE | ASSURE-19 Begins Clinical Testing to Acquire FDA Emergency Use Authorization

PRESS RELEASE | ASSURE-19 Begins Clinical Testing to Acquire FDA Emergency Use Authorization

by Oceanit | Aug 25, 2020 | General

PRESS RELEASE | ASSURE-19 Begins Clinical Testing to Acquire FDA Emergency Use Authorization Oceanit and the Queen’s Medical Center have started patient trials with ASSURE-19 rapid point-of-need Covid-19 tests as of Saturday, August 22. Oceanit is collaborating with...
« Older Entries

Recent Posts

  • New 2025 COVID Vaccine Rules: What They Mean for Americans
  • Summer 2025 COVID Trends: What to Know & How to Stay Safe
  • CDC Updates 2025 COVID-19 Testing, Isolation & Recovery
  • WHO Pandemic Treaty Aims to Prevent Future Health Crises
  • Should You Keep Rapid Tests for Spring & Summer 2025?

Recent Comments

No comments to show.
Copyright 2025 Oceanit Foundry LLC. The ASSURE-100 Rapid COVID-19 Test has not been FDA cleared or approved, but has been authorized by FDA under an EUA. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
[dsm_icon_list list_alignment=”flex-end” _builder_version=”4.27.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” list_alignment_last_edited=”on|phone” list_alignment_phone=”center” sticky_enabled=”0″ list_alignment_tablet=”flex-end”][dsm_icon_list_child text=”Privacy Policy” use_icon=”off” url=”/privacy-policy/” _builder_version=”4.27.4″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_text_color=”#e8e8e8″ text_font_size=”12px” text_text_color_last_edited=”off|desktop” global_colors_info=”{}” text_text_color__hover_enabled=”on|desktop” text_text_color__hover=”#1e73be”][/dsm_icon_list_child][/dsm_icon_list]